Norris Perne & French LLP Bluebird Bio, Inc. Transaction History
Norris Perne & French LLP
- $1.3 Billion
- Q2 2024
A detailed history of Norris Perne & French LLP transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Norris Perne & French LLP holds 10,000 shares of BLUE stock, worth $5,699. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$5,699
Previous $12,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BLUE
# of Institutions
162Shares Held
79.9MCall Options Held
525KPut Options Held
634K-
Black Rock Inc. New York, NY15.4MShares$8.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$5.87 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN6.39MShares$3.64 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.15MShares$2.93 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$2.66 Million0.02% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $44M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...